Current and Emerging Treatment Options for HER2‑Positive Gastroesophageal Cancer
DOI:
https://doi.org/10.58931/cot.2024.1220Abstract
Gastroesophageal cancer (GEC) is the fifth most common cancer and the second most common cause of cancer-related mortality, with 1.3 million annual deaths worldwide. The global incidence is increasing, particularly among younger patients. GEC can be classified into subtypes based on anatomic location, histology, molecular characteristics, or tumour biology and genomics. In approximately 20% of all GECs overexpression of HER2 is identified. The landscape of treatment options in this patient population is evolving rapidly. This review summarizes the progress of HER2-directed therapies for advanced disease and highlights future directions in targeting the disease.
The epidermal growth factor receptor (EGFR) family of transmembrane tyrosine kinase receptors, EGFR/HER1, HER2/neu, HER3, and HER4, all have an extracellular ligand-binding domain, lipophilic transmembrane domain, and an intracellular domain with tyrosine kinase activity, binding to these receptors results in activation of downstream RAS/MAPK and PI3K/AKT pathways. In turn, this induces cell proliferation, differentiation, migration, and survival. The phase III Trastuzumab for Gastric Cancer (ToGA) trial reported the incidence of HER2-positive gastric cancer to be 22%. Therefore, targeting HER2 and its downstream signaling pathways holds important potential as a therapeutic strategy. Figure 1 illustrates potential targeting mechanisms that will be discussed in this review.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660
Liu CQ, Ma YL, Qin Q, Wang PH, Luo Y, Xu PF, et al. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac Cancer. 2023;14(1):3-11. DOI: https://doi.org/10.1111/1759-7714.14745
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. DOI: https://doi.org/10.3322/caac.21708
Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. Int J Mol Sci. 2020;21(11). DOI: https://doi.org/10.3390/ijms21114012
Van Cutsem E, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476-84. DOI: https://doi.org/10.1007/s10120-014-0402-y
Wang F, Ba Y. Treatment strategies for patients with HER2-positive gastric cancer. Cancer Biol Med. 2024;20(12). DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0480
Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol. 2001;12 Suppl 1:S3-8. DOI: https://doi.org/10.1093/annonc/12.suppl_1.S3
Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467-72. DOI: https://doi.org/10.1038/nature25432
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. DOI: https://doi.org/10.1016/S0140-6736(10)61121-X
Park YS, Hwang HS, Park HJ, Ryu MH, Chang HM, Yook JH, et al. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? Hum Pathol. 2012;43(3):413-22. DOI: https://doi.org/10.1016/j.humpath.2011.05.019
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-30. DOI: https://doi.org/10.1016/S1470-2045(19)30863-0
Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Siddiqui A, et al. Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial. Gastric Cancer. 2023;26(1):123-31. DOI: https://doi.org/10.1007/s10120-022-01335-4
Lee CK, Rha SY, Kim HS, Jung M, Kang B, Che J, et al. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nat Commun. 2022;13(1):6002. DOI: https://doi.org/10.1038/s41467-022-33267-z
Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21(6):821-31. DOI: https://doi.org/10.1016/S1470-2045(20)30169-8
Yamashita K, Iwatsuki M, Yasuda-Yoshihara N, Morinaga T, Nakao Y, Harada K, et al. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. Br J Cancer. 2021;124(3):595-603. DOI: https://doi.org/10.1038/s41416-020-01138-3
Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-30. DOI: https://doi.org/10.1038/s41586-021-04161-3
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197-208. DOI: https://doi.org/10.1016/S0140-6736(23)02033-0
Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial. J Clin Oncol. 2016;34(5):443-51. DOI: https://doi.org/10.1200/JCO.2015.62.6598
Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. J Clin Oncol. 2014;32(19):2039-49. DOI: https://doi.org/10.1200/JCO.2013.53.6136
Strickler JH, Nakamura Y, Yoshino T, Catenacci DVT, Janjigian YY, Barzi A, et al. MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in Progress. Journal of Clinical Oncology. 2021;39(3_suppl):TPS252-TPS. DOI: https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS252
Cytryn SL, Janjigian YY. HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers. J Natl Compr Canc Netw. 2023;21(4):423-9. DOI: https://doi.org/10.6004/jnccn.2023.7010
Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, et al. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer. 2016;139(12):2859-64. DOI: https://doi.org/10.1002/ijc.30408
Seo S, Ryu MH, Park YS, Ahn JY, Park Y, Park SR, et al. Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3). Gastric Cancer. 2019;22(3):527-35. DOI: https://doi.org/10.1007/s10120-018-0891-1
Klein-Scory S, Ladigan-Badura S, Mika T, Verdoodt B, Tannapfel A, Pohl M, et al. Liquid biopsy based HER2 amplification status in gastric cancer patients indicates clinical response. Heliyon. 2023;9(11):e21339. DOI: https://doi.org/10.1016/j.heliyon.2023.e21339
Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. N Engl J Med. 2020;382(25):2419-30. DOI: https://doi.org/10.1056/NEJMoa2004413
Van Cutsem E, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744-56. DOI: https://doi.org/10.1016/S1470-2045(23)00215-2
Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, et al. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24(7):772-82. DOI: https://doi.org/10.1016/S1470-2045(23)00242-5
Ku G, Elimova E, Denlinger CS, Mehta R, Lee KW, Iqbal S, et al. 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA). Annals of Oncology. 2021;32:S1044-S5. DOI: https://doi.org/10.1016/j.annonc.2021.08.1489
Elimova E, Ajani JA, III HAB, Denlinger CS, Iqbal S, Kang Y-K, et al. Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). Journal of Clinical Oncology. 2023;41(4_suppl):347-. DOI: https://doi.org/10.1200/JCO.2023.41.4_suppl.347
Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, et al. HERIZON-GEA-01: Zanidatamab + chemo +/- tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma. Future Oncol. 2022;18(29):3255-66. DOI: https://doi.org/10.2217/fon-2022-0595
Peng Z, Liu T, Wei J, Wang A, He Y, Yang L, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond). 2021;41(11):1173-82. DOI: https://doi.org/10.1002/cac2.12214
Piha-Paul SA, Gupta M, Oh D-Y, Kim YH, Rha SY, Kang Y-K, et al. Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cancer Research. 2022;82(12_Supplement):CT122-CT. DOI: https://doi.org/10.1158/1538-7445.AM2022-CT122
Maglakelidze M, Ryspayeva DE, Andric Z, Petrovic Z, Bulat I, Nikolic I, et al. HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis. Journal of Clinical Oncology. 2023;41(4_suppl):289-. DOI: https://doi.org/10.1200/JCO.2023.41.4_suppl.289
Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. 2018;9(10):867-78. DOI: https://doi.org/10.1007/s13238-017-0384-8
Lumish MA, Maron SB, Paroder V, Chou JF, Capanu M, Philemond S, et al. Noninvasive Assessment of Human Epidermal Growth Factor Receptor 2 (HER2) in Esophagogastric Cancer Using (89)Zr-Trastuzumab PET: A Pilot Study. J Nucl Med. 2023;64(5):724-30. DOI: https://doi.org/10.2967/jnumed.122.264470
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Canadian Oncology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
